CA1230186A - Cross-linked gels of hyaluronic acid and products containing such gels - Google Patents

Cross-linked gels of hyaluronic acid and products containing such gels

Info

Publication number
CA1230186A
CA1230186A CA000481055A CA481055A CA1230186A CA 1230186 A CA1230186 A CA 1230186A CA 000481055 A CA000481055 A CA 000481055A CA 481055 A CA481055 A CA 481055A CA 1230186 A CA1230186 A CA 1230186A
Authority
CA
Canada
Prior art keywords
cross
sodium hyaluronate
weight
gel
hyaluronic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000481055A
Other languages
French (fr)
Inventor
Endre A. Balazs
Adolf Leshchiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomatrix Inc
Original Assignee
Biomatrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomatrix Inc filed Critical Biomatrix Inc
Application granted granted Critical
Publication of CA1230186A publication Critical patent/CA1230186A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/731Cellulose; Quaternized cellulose derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/735Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

ABSTRACT OF THE DISCLOSURE

Disclosed are cross-linked gels of hyaluronic acid, alone or mixed with other hydrophilic polymers and containing various substances or covalently bonded low molecular weight substances and processes for preparing them. These products are useful in numerous applications including cosmetic formu-lations and as drug delivery systems.

Description

1.2;~01~3~

The present invention relates to gels and mixed gels of hyaluronic acid (~A), formulations containing them and methods for preparing them.

Ilyaluronic acid is a well known, naturally occurring polysaccharide containing alternating N-acetyl-D-glucosamine and D-glucuronic acid monosaccharide units linked with B 1->4 bonds and the disaccharide units linked with ~ 3 glycoside bonds. Hyaluronic acid usually occurs as the sodium salt. The molecular weight of HA is generally within the range of 50,000 up to 8 x 106 and even higher.
The prior art describes the cross-linking of HA with the use of 1, 2, 3, 4-diepoxybutane in alkaline medium at 50C.
(T.C. Laurent, K. Hellsing, and B. Gelotte, Acta Chem. Scand.
18 [1984], No 1, 274-5). The product obtained by that method is a gel which substantially swells in water.
It is also known that divinyl sulfone (DVS) is used for cross-linking polysaccharides, especially cellulose (U.S.
Patent No. 3,357,784).
The present invention will be described with refere~ce tv the acc~anylng ~rawings, in wnicn:-FIG. 1 is a graphical representation of the experimen-tal data set forth in Example 3 below; and FIG. 2 is a graphical representation of the experimen-tal data set forth in Example 4 below.

In one aspect thereof, the present invention provides highly swollen sels of o~oss-linked hyaluronic acid.
In another aspect, the invention provides mixed cross-linked gels of hyaluronic acid and other hydrophillic ~,- polymers.

123~018~

In yet another aspect, the invention provides cross-linked gels of hyaluronic acid and other polymers Eilled with various substances.
In still another aspect, the invention pxovides cross--linked gels of hyaluronic acid containing low molecular weight substances covalently attached to the macromolecules.
In still yet another aspect, the invention provides various formulations containing cross-linked hyaluronic acid gels.
Finally, the invention provides the methods o~ pre-paring the products of the invention.
The present invention is based on the obser~ation that divinyl sulfone (DVS~ reacts readily with HA in aqueous alkaline solutions at room temperature, i.e., about 20C, thereby providing cross-linked ~A gels. As used herein, the term H~ means hyaluronic acid and its salts such as the sodium, potassium, magnesium, calcium, etc. salts. These gels swell in water and water containing media. The swelling ratio de-pends upon the degree of cross-linking of the gel. We have found that the degree of cross-linking can be controlled by changing several factors including the molecular weight of the EIA, its concentration in the reaction mixture, the alkali concentration and the polymer/DVS ratio. The reaction is very fast and in most cases a strong gel can be obtained in several minutes. The swelling ratio of these gels can be from 20 up to 8000, and more, depending upon the reaction parameters.
It has also been found that the swelling ratio of cross-linked E~A gels is substantially greater than the swelling ratio of cross linked ~els of other polysaccharides obtained ~ -2-1~3~36 under the same reaction conditions. This can probably be explained by the unique nature of ~IA (as compared to other polysaccharides) and its water solutions. We have found that in water, a large molecule of HA forms a very flexible, long random coil which takes up an extremely large volume in the solution. For example, the specific volwne of a hydrated HA
molecule in a physiological salt solution is about 2-6 x 103 ml/g. That means that in a quite low concentration water solution of HA, a steric exclusion phenomenon occurs which will substantially affect not only the physico-chemical pro-perties of the solution, but the reaction of the ~A with low molecular weight substances as well. In other words, the nature of the ~A solutions affects the degree of cross-linking and the behavior of the cross-linked gel, in a manner quite unlike anything that occurs with other polysaccharides.
We have also found that this unique property of HA
to give highly swollen cross-linked gels can be used to effect modification of the properties of cross-linked gels made of mixtures of IIA with other hydrophillic polymers. These polymers include other polysaccharides, synthetic and natural, such as hydroxyethyl cellulose, carboxymethyl cellulose, xanthan gum, chondroitin sulfate, heparin, proteins of various types, such as collagen, elastin, albumin, a globulin, etc., sulfated proteins such as keratin sulfate and sulfated aminoglycosamino-glycans, synthetic water-soluble polymers, such as polyvinyl alcohol and its cv-polymers, co-polymers of poly-~hydroxethyl) methacrylate and the like. In other words, any polymer soluble in water or water alkaiine solutions and containinq groups capable of reacting wi~h DVS, namely, hydroxyl, amino or sulfy-hydryl groups, can be used to obtain highly swollen cross-linked mixed gels vf ll~.

,s ~, _ i2301~36 We have further found that us~ful products can easily be obtained by carrying out the cross-linking reaction of HA
in the presence of low-molecular weight substances containing reactive groups of the mentioned types.
Another type of material according to the present invention is a cross-linked hydrophillic gel filled with various water insoluble substances including hydrocarbons, such as petrolatum; an oil or fat such as beeswax,C~cn~lt oil or lanolin, pi~ts, su~ as kaolin, ferric oxide; ins~luble dyes, polymers, SU~I as polye-thylene, polyetrafluro ethylene, etc. In this type of product fine par-ticles of a filler are immobilized in a gel network or in what we call a "polymer cage". This latter product can be very useful for several purposes which will be discussed in more detail below.
The processes by which the hereinabove described pro-ducts are obtained will now be discussed in detail.
In order to ohtain a cross-linked ~l~ gel, a sample of sodium hyaluronate or hyaluronic acid from any source is dissolved in dilute alkaline solution. The molecular weight of HA can be from 50,000 up to 8 x 106 and even higher. The molecular weight affects the reation - the higher the molecular weight the greater the possibility to obtain a cross-linked yel.
The alkali concentration in the reaction mixture can be from 0.005 M to 0.5 M and h~gher. I'he lower limit is dic-tated by the necessity to have the pil of the medium not lower than 9 and the upper limit by tlle hydrolysis of ~IA in an al-kaline solution. Vsually, a decrease in alkali concentration results in ~3els wi~h a ~reater swelling ratio, probably because a small r3lnount of DV5 takes part in the cross~linking reaction.

~L~301~36 The concentration of ~A in the starting solution can vary from 1% by wei~ht up to 8~ by weight and higher.
When the concentration s below the lower limit, a cross-linked gel cannot be obtained even at a low HA/DVS ratio.
When the concentration is too high, the solution becomes SQ
viscous that it is difficult to handle it. The HA concentra-tion substantially affects the swelling behavior of the gels (FIG. 1). It was found that the shape of the curve for the swelling ratio - the HA concentration dependence is essen-tially the same for various HA/DVS ratios but the lower this ratio (i.e., more DVS in the mixture), the less the swelling ratio of the cross-linked gel for the same concentration of ~A in the starting mixture.
We have found that HA/DVS in the reaction mixture is another parameter which can be conveniently used to control the swelling ratio of the cross-linked HA gel. An increase in the ratio results in highly swollen soft ~els (the swelling ratio is about 4000 and higher) whereas hard and less swollen gels are obtained when this ratio is decreased. In general, the HA/DVS weight ratio can be from 15:1 to 1:5 and lower.
The cross-linking reaction is usually carried out at room temperature, i.e., about 20C, but it can be performed at a lower or higher temperature, if desired. However, it should be kept in mind that HA can degrade relatively rapidly in alkaline solutions at elevated temperatures and, if such degradation occurs, the decrease in MW can affect the proper-ties of the obtained gels.
The cross-linking reaction is relatively fast and strong gels are formed ~sually in several minutes when the HA

~f ' ,, 123~86 concentration is high enough and the HA/DVS ratio is low. But even at low HA concentration in the reaction mixture, the gel formation starts usually 5~10 minutes after addition of DVS. We have found that in most cases one hour is enough S for completion of the cross-linking reaction.
Another method of controlling the swelling ratio o cross-linked liA gels involves adding neutral salt to the reaction mixture. We have found that the swelliny ratio of the gels obtained in the presence of water soluble neutral salts, such as the chlorides, sulfates, phosphates and aoetates of alkali metals, decreases with the increase of salt concentration.
salt can be used in concentration up to 20 wt. ~ and higher, depending upon the nature of the salt and its effect on the solubility of HA in the reaction mixture.
To obtained cross-linked gels of other hydrophillic polymers the same reaction conditions as for HA can be used.
The swelling ratio of these gels can be conveniently controlled by incorporating I-IA into the gel structure. ~hen the mixed gels are obtained, the composition of the polymer mixture can vary over a broad range depending on the swelling ratio o~
the cross-linked gel desired. The preferred content of HA
in the mixture is from 5 to 95 wt. ~.
Cross-linked gels of ~IA or other polymers or mixed cross-linked cJels filled with inert substances are obtained by incorporating -these substances into the reaction mixture be-fore the adclition of DVS. These inert substances are, pre-ferably, water-insoluble liquids or solid substances. Examples of such substances are petrolatum and ~aolin. To obtain a fillecl cross-~inked gel~ a chosen substance (based on a con sideration of tne desired properties of the gel) is emulsifiecl , ~,.

30~36 or dispersed in an alkaline solution of ~iA or other polymer or mixture of HA with o-ther polymer or polymers and DVS is added to the ~ixture. The amount of DVS and the other para-meters of the reaction are selected depending upon the desired properties of the gel. The relative amount of filler in the gel can vary over a broad range and is from 1 to 95 wt. ~
calculated on the total amount of polymers and filler, pre-ferably from 5 to 90 wt. ~.
Cross~linked gels containing low molecular weight substances such as drugs, dyes and others covalently attaehed to the macromolecular network are obtained, preferably by incorporating the named substances into an ~IA or HA and other polymers solution before the addition of DVS. An example of such a substance is carminic acid, an FD~ approved substanee for use in food an~ drug preparations.
It is probably the presenee of a glueosidic moiety of the carminic molecule which takes part in the cross-linking reaction with DVS. It should be understood that a great number of substances can be used to obtain a modifiecl cross-linked gel of this type. The only essential feature of these sub~
stanees is that they eontain chemieal groups with aetive hy-drogen atoms reactive to DVS. The amount of sueh low moleeular wei~ht substances which ean be used in the reaetion depends upon the desired level of that substance in the gel. This amount ean be in the range of from 1 to 9~ wt. ~ as eale~lated on polymer content in the gel, preferably, 5 tv 90 wt. ~.
The cross-linked i~A and mixed gels obtained aeeording to the present in~ention ean be used for many purposes. We have founcl that these highly s-Jollen gels are very useful in ~ -7-1'~3~
cosmetic formulations and can be considered as water-retaining and water-delivering ingredients in these formulations.
As HA is known to be a biologically tolerable polymer in the sense that it does not cause any immune or other kind of res-ponse when introduced into a human body, the cross-linked HA gels can be used for various medical applications. The cross-linked gels modified with other polymers or low molecular weight sub-stances can be used as drug delivery devices. For example, we have found that heparin introduced in a cross-linked HA gel re-tains its antithrombogenic activity.
We have also found that cross-linked gels of HA can slow down the release of a low molecular weight substance dis-persed therein but not covalently attached to the gel macro-molecular matrix.
The domain of the cross-linked hyaluronic acid (alone or co-polymerized with other polyanionic or neutral polymers) forms a molecular cage. In this cage, hydrophillic or hydro-phobic molecules of various pharmacological or biological ac-tivity can be dispersed. Thus, the cage constitutes a depot for these substances of various molecular size. The substances contained in the domain of the molecular cage will be delivered into the environment by diffusion. The delivery process is controlled by such factors as the exclusion volume effect and the pore size of the molecular cage and by the molecular inter-action between the polymeric network and the substance contained therein. Thus, the molecular cage forms a depot for the con-trolled delivery of drugs or other substances to the skin or other tissues.

~ -8-01~36 There is one additional property of the cross-linked HA gels which makes them potentially very useful as drug de-livery devices. The swelling ratio of these gels in water depends substantially upon the salt concentration in the medium and decreases several times with an increase in salt concen-tration. This means that a gel swollen in water will ~ontract substantially when introduced into the body (because of the normal salt content of the body fluids and tissues), thus delivering its contents, i.e., an incorporated drug, into the body tissue.
The cross linked gels filled with various substances can also be used in cosmetic formulations. For example, a gel with petrolatum incorporated therein gives all the benefits of using petrolatum in cosmetic formulations without the unpleasant greasy feeling which is normally observed with petrolatum con-taining formulations.

~ A-1,~30~86 The present lnvention is described in more detail in the following ~ S ~ wherein all parts given are by weight unless otherwise indicated. These ~xampl~ are given merely by way of illustration and are not intended to limit the inven-tion as set forth in the claims.
Example 1 This Ex~~ illustrates the effect of varying ~A molecu-lar weight on the cross-linking reaction.
0.3410 g. of sodium hyaluronate ohtained from rooster combs (intrinsic viscosity in 0.15 M solution of ~laCl [n] 3850, MW about 2.5 x 106) was mixed with 8.1840 g. of 0.2 M NaOH solu-tion to give a 4% by weight solution after stirring for 30 minutes. Then, 0.0721 g. o~ DVS was stirred into the solution.
The weight ratio HA/DVS was about 4.7. A strong gel formed in about 15 minutes. The gel was left for one hour and then put into one liter of distilled water. The gel was left to swell in water overnight. Then it was broken into small particles by vigorous stirrin~ in water. The gel particles were filtered of~ and washed several times with water. Colorless, water clear particles were obtained. To determine the swelling ratio of the gel, a sample weighing about 1 g. was centrifuged in a glass filter at 3,000 rpm for two hours. Then the particles left on the ilter were hydrolyzed with 2 ml of lN ~]2SO4 solution for three hours at 95-98C. The clear solution obtained was neutralized upon coolin~ witll 2 ml of lN NaO~I solution and the glucuronic acid content was determined b~ the carbazole method ~An ~utomated Method ~or The ~etermination Of llexuronic Acids, Analytical Uiochernistry, 2, 517-55~ [1965]). ~he ll~ content in the starting ~el ~as calculated and the swellin~ ratio was ~ _9_ 12~,~186 expressed as 100/[HA]%, where [IIA]~ is a percent of ~A in the swollen gel.
The swelling ratio in water of the gel obtained was 820.
ThisExan~le was repeated with the exception that the solution of HA in alkali was kept at room temperature for 24 hours. This led to a HA hydrolysis. The intrinsic viscosity [n] of the polymer was 1064 which corresponded to a MW of about 0.5 x 106. A cross-linked gel could not be obtained from this polymer at the IIA/DVS ratio used above.
The F~ai~le with the degraded HA was repeated but the HA/DVS ratio used was about 2. A cross-linked yel was obtained which had a swelling ratio in water of 2910.
Example 2 This ~ar~le illustrates the effect of alkali concentra-tion on the cross~linking of HA.
A sample of HA with a MW of about 3 x 106 was dissolved in a calculated amount of 0.2M NaO~I solution to give 4~ viscous solution to which DVS was added in an amount providing an HA/DVS
ratio of about 5:1. The cross-linking and treatment of the gel was carried out as described in the preceding example. The swelling ratio of the gel in water was 990.
The Exal~le was repeated but the alkali concentration was 0.01M. A gel was obtained with a swelling ratio in water of 3640. Thus, a decrease in the alkali concentration in the reaction mixture results in a gel with substantially great~r swelling in water.
Example 3 -This ~xal~le illustrates the effect oE varying the HA
concentration in the star~ing mixture on the swelling behavior ~o of th~ resultirlg gel.

~?, ~'3~186 Eight solutions of sodium hyaluronate in 0.2M sodiurn hydroxide solution were prepared with the HA concentration being 2.0, 2.5, 3.Q, 3.5, ~.0, 5.5, 8.0 and 10.0~ by weight respectlvely. To each solution a calculated amount of DVS was added to have a weight ratio of ~I~/DVS about 1 (molar ratio ahout 0.33). The cross-linked gels were obtained as described in the above examples and treated accordingly. The swelling ratio was determined for each sample and plotted against starting HA concentration. The results are shown in FIG. 1.
Example 4 This example illustrates the effect of varying the HA/DVS
ratio on the swelling behavior of the resulting gel.
Six solutions of sodium hyaluronate in 0.2M sodium hydroxide solution were prepared with a concentration of 4.0~
by weight. To each solution a calculated amount of DVS was added to have the following l~A/DVS ratios: 0.2, 0.3, 0.5, 1.0, 1.5 and 2.0 mole/mole. The cross-linked gels were obtained and treated as described in the preceding examples. The swelling ratio was determined for each sample and plotted against IIA/DVS
ratio in the reaction mixture. The results are shown in ~IG. 2.
Example 5 . . .
This example illustrates the effect of sodium chloride in the reaction mixture on the swelling ratio of the cross-linked gel.
Two samples of the cross-linked HA gel were prepared with the use of the above described procedure. 5Odium hyaluronate concentration in 0.2~l sodium hydroxide was 4~ by weight. The HA/DVS ratio was about 5:1, the xeaction time one hour. To the second reaction mixture s~odium chloride was added in an amount ~r ' A~ i' 1 1 3LZ31D~36 to have a 1.0 molar salt concentration. The swelling ratio of the first gel was 238Q, whereas the gel obtained in the presence of salt had a swelling ratio in water of 650.
Example 6 This example illustrates the cross-linking of hyroxy-ethyl cellulose with the use of DVS.
0.4312 g. of air-dry hydroxyethyl cellulose (Cellosize QP-100000 ~ , Union Carbide) was dissloved with stirring in 10.3 g. of 0.2N sodium hydroxide to give 4~ by weight. 0.0855 g. of DVS was stirred into this solution (polymer/DVS ratio was about 5:1 by we:ight) and the mixture was left for one hour at room temperature. A cross-linked gel was obtained which was pro-cessed as described in Example 1. To determine the polymer concentration in the gel and, hence, the swelling ratio, a weighed sample of the gel was put into acetone, kept overnight, washed several times with acetone and dried in a vacuum oven at 50C to a constant weight~ The swelling ratio of the gel obtained was 43 which is substantially less than for cross-linked lIA gel obtained under the same reaction conditions.
Example 7 This example illustrates the cross-linking of xanthan gum with the use of DVS.
0.4935 g. of air-dry xanthan gum (Kelzan ~ , Kelco) was dissolved in 11.3 g. of 0.2M sodium hydroxide solution to give a 4% by weight solution. To this solution 0.0718 g. of DVS was added (the polymer/DVS ratio was about 7:1 by weight).
The mixture was kept for an hour at room temperature. The cross-linked gel finally obtained was put into a large volume of water, left to swell overnight and broken into small pieces which were extensively washed with water.

~ -12-1~0'1 ~36 The swelling ratio of the gel determined by the weight metho~ described in the preceding example was 52~, which is substantially less than for cross-linked ~l~ gel obtained under the same reaction conditions.
Example 8 This example illustrates the cross-linking of a cationic water-soluble cellulose polymer with the use DVS.
0.5483 g. of a cationic cellulose polymer obtained by chemical modification of hydroxyethyl cellulose (Polymer Ucare JR ~ , Union Carbide) was dissolved in 13.71 g~ o~ 0.2~ sodium hydroxide solution to give a 4~ by weiclht solution to which 0.0849 g. of DVS was added (the polymer/DVS ratio was about 6.5:1). The reaction mixture was left to stand for an hour at room temperature and the gel obtained was processed and analyzed as described in the preceding example. The swelling ratio of the gel in water was 386, which is substantially less than that for a cross-linked HA gel obtained under the same reaction conditions.
Example 9 This example illustrates the cross-linking of carboxy-methyl cellulose with the use of DVS.
0.4703 g. of carboxymethyl cellulose sodium salt (9H
4F, Hercules) was dissolved in 11.76 g. of 0.2M NaOH to give a 4% by weight solution to which 0.0651 g. of DVS was added (the polymer/DVS ratio was about 7:1). The reaction mixture was kept for an hour at room temperature and the gel obtained was processed and analysed as described in the preceding example.
The swelling ratio in water was 893, which is more than that obtained for other cellu~losic polymers but less than ~or cross-linked ll~ gel.

~, -, ~ ~13-~ 23(~186 Examples 10-13 These examples illustrate mixed cross-linked gels made of HA and carLoxymethyl cellulose and the effect of the EIA
content on the swelling ratio of the gels.
In each example, sodium hyaluronate and carboxymethyl cellulose 9H4F were dissolved in 0.2M sodium hydroxide solution in such amounts as to provide speciEic ratios of the two polymers.
In all cases the total polymer concentration was 4~ by weight and the polymer/DVS ratio was about 5:1. The gels were obtained and processed as described above. The polymer content in the gels was determined as described in Example 1, with the exception that the hexos.~mine concentration (instead of glucoronic acid) was determined by a known method (A Rapid Procedure for the Estimation of ~mino Sugars on a Micro Scale, Analytical Bio-chemistry 15, 167-171 [1966J) in the hydrolyzate. The polymer content was calculated from the HA concentration and the ratio of the two polymers.
~iA Content in the StartingSwellin~ Ratio Mixture, Wt. ~ in Water Example 1070 8196 Exanple 1150 6757 Example 1220 1117 Example 13 0 623 As can be seen from these data, an increa~e in the ~-IA
content in the starting mixture results in an increase in the swellin~ ratio of the resulting gels.
Example 1~
This example illustrates mixed cross-lin~ed gels ob-tained from ~IA and collagen.
\

,~, i~3C~6 0.2531 g. of dry sodium h~aluronate was dissolved in 2.5r~ of O.lM sodium hydroxide solution. 0.063 g. of collagen obtained from human umbilical cord was dissolved in 2.3 ml o~ O.lM acetic acid and the two solutions were combined. The total polymer concentration was 6 wt. ~ and the weight ratio HA/collagen was about 4:1. 0.05 g. of dry KCl was dissolved in the mixed solution and DVS was stirred into the reaction mixture in an amount providiny a polymer/DVS ratio of about 5:1. The reaction mixture was ~ept at room temperature for an hour and the gel obtained was treated as described above. The polymer content in the swollen gel was calculated from the HA content which was found by the glucuronic acid assay. A strong and resilient gel was obtained which had a swelling ratio in water of 321.
Example 15 I'his example illustrates a mixed cross-linked HA-collagen gel with a higher content of collagen and a lower swelling ratio than the gel described in Example 14.
0.2544 g. of sodium hyaluronate was dissolved in 3.5 ml of 0.2M sodium hydroxide solution. 0.1192 g. of collagen obtalned from human umbllical cord was dissolved in 1.5 ml of 0.2M acetic acid solution and the solutions were combined. The total polymer concentration was 7.5 wt. % and the weight ratio HA/coliagen was about 2:1. 0.05 g. of sodium chloride was dissolved in the mixed solution to which 0~1189 g. of DVS
was added, thus providing a polymer/DVS ratio o~ about 3:1 by weight. The ge1 was obtained and processed as ~escribed in the preceding example. A strong gel was obtained with a swelling ratio of 35.

~ --15--, .~

1~30~36 Example 16 This example illustrates a mixed cross-linked gel of ll~ anc~ heparin.
0.2968 g. of dry sodium hyaluronate was dissolved in 6.92 g. of 0.2M sodium hydroxide solution to give a 4 wt. ~
solution to which 0.0503 g. of heparin was added. The heparin content calculated on the basis of the total amount of polyrners was 14.5 wt. ~. 0.0590 g. of DVS was stirred into the mixture.
The reaction was carried out for an hour at room temperature.
The obtained gel was processed as described in the preceding examples. The swelling ratio of the gel was 625.
Example 17 This example illustrates a cross-linked hydroxyethyl cellulose gel filled with petrolatum.
0.5292 g. of dry hydroxyethyl cellulose was dissolved in 10.58 g. of 1 M sodium hydroxide solution and 1,058 g. of white petrolatum was stirred into the solution. The petrolatum/
polymer ratio was about 2. A solution of 0.1771 g. of DVS in 1.0 g. of 1 M sodium hydroxide solution was added to the emul-sion with vic30rous stirring. The reaction mixture was left for an hour at room temperature and the gel obtained was treated as described n the above examples. To find the petrolatum content in the gel, a gel s~nple was digested with 2 ml of lN il2S0~ a~ 95C for three hours. Then 2 ml of lN ~laOH was added to the mixture followed by 4 ml of xylene to extract the petrolatum. The extract was dried off in vacuum and the residue was weighed. The calculated petrolat~n content ln the gel was 6 wt. ~.
\

123~86 ~xample 18 This example illustrates a mixed ~A-carboxymethyl cellulose gel filled with petrolatum.
0.1830 g. of dry sodium hyaluronate and the same amount 5-- of carboxymethyl cellulose were dissolved in 9.1 g. of 0.2 N
sodium hydroxide solution to give a 4 wt. % solution of polymer.
0.3660 g. of petrolatum was stirred into the solution and ~.0730 g. of DVS was added to the resulting emulsion with vigorous stirring. The polymer/DVS ratio was about 5:1. The reaction mixture was left for an hour at room temperature. The obtained gel was processed as described in the preceding example. The swelling ratio of the gel determined through hexosamine content was 738 and the petrolatum content determined as in the pre-ceding example was 0.1 wt. %.
Example 19 This example illustrates a cross-linked HA gel filled with kaolin.
0.2700 g. of dry sodium hyaluronate was dissolved in an amount of 0.2N sodium hydroxide solution sufficient to ob-tain a 4 wt. % solution of the polymer. 0.5400 g. of kaolin was stirred into the solution. 0.0540 g. of DVS was added to the suspension and the reaction mixture was left for an hour at room temperature. The gel formed was left to swell in a large volume of water. The highly swollen gel was broken into small particles by pushing it through a syringe with a needle.
The particles were extensively washed with water. Milky white, highly swollen particles were obtained. The concentration of solids in the gel was 0.064 wt. ~.
\

f~. -17-1~:30186 Example 20 This example illustrates a cross-linked HA gel con-taining carminic acid covalently attached to the macromolecular network.
0.20 g. of dry sodium hyaluronate and 0.04 g. of carminic acid were dissolved in 5.0 ml of 0.2M sodium hydroxide solution to give an approximately 4 wt. ~ solution of polymer. 0.40 g.
of DVS was added to the solution (polymer/DVS ratio was 1:2) and the mixture was left for an hour at room temperature. The gel obtained was processed as described in the preceding examples.
Red colored transparent gel particles were obtained and the color did not disappear after extensive washing with water. The swelling ratio in water determined by the weight method was llS.
Example 21 This example illustrates the effect of salt concentra-tion in water on the swelling behavior of a cross-linked HA gel.
A cross-linked HA gel was obtained as described in the preceding examples with an HA concentration in 0.2M NaOH of 4 wt. %; HA/DVS ratio 5:1, at room temperature for one hour.
The gel particles were put into water and aqueous sodium chloride solution of different concentrations and the swelling ratios were determined. The following results were obtained:
_ C1 Concentration, M Swellin~ ~atio Water 990 0.05 413 0.15 384 .50 219 1.00 ~ 176 ~230~6 Example 2_ This example illustrates the biological activity of a mixed HA-heparin cross-linked gel.
Fine particles of the mixed HA-heparin cross-linked gel prepared according to Exarnple 16 were mixed with normal human plasma in amounts providing concentrations of cross-linked HA of 0.01, 0.02 and 0.04% and the clotting time of the samples increased respectively by 1.4, 2.8 and 5.0 times. Identical concentrations of non-heparin containing, cross-linked gel pa~ticles had no effect on clottinc3 time.
These data indicate that heparin does not lose the ability to inhibit thrombin-catalyzed fibrin formation when it is incorporated into a cross-linked gel structure.
Example 23 .
This example illustrates a product containing cross-linked ~IA gel particles useful for cosmetic formulations.
~ cross-linkecl HA gel was prepared as described in Example 1 under the following reaction conditions: IlA concen-tration 3.0 wt. %, sodium hydroxide concentration 0.2 M, ~A/~VS
ratio about 3:1, room temperature, time one hour. The gel was allowed to swell in a large volume of ~ater overnight, then was broken into small particles by pushing through a syringe with a needle oE 18-1~2 gauge and then through a syringe with a needle of 25-1/2 gauge. The particles were thoroughly washed with water. Optically clear, colorless particles were obtained.
~he swelling ratio of the gel was 1980. The HA collcentration of the filtered c3el particles was 0.0Z5 wt. &. These particles were used in mixtures Wit}l high molecular weight polyethylene oxide (Polyox ~ Coagulant,~ Union Carbine) and soluble so~ium ~o hyaluronate ~EIyalderm ~ , Biomatrix, Inc.) of the following composition:
;., ,~

1~30~

Parts By Weight:
Ingredients Mixture 1 Mixture 2 Mixture 3 Cross-linked gel 90 80 75 Hyladerm ~ solution of sodium hyalurona~) 5 2 14 Polyox ~ 1~ solution in water 5 4 11 Water - 14 All of these formulations had the appearance of homogeneous viscous liquids even though they were heterogeneous by the na-ture of the ingredients. When appled to the skin they gave a very soft, silky feeling.
Example 24 This example illustrates a moisturizing eye cream containing a cross-linked liA gel according to the present in-vention.

% By Weight A. Carbopol ~Y940 (B.~. Gocdrich) 0.4 Mixture #3 (Example 23)10.0 Wa-ter 83.3 B. Volpo ~ -3 (Croda, Inc.)1.0 Volpo ~ -5 (Croda, Inc.)0.5 Solulan ~ C-24 (Amerchol Co.) 1.8 Roban ~ 1.0 Crodamol ~ PMP (Croda, Inc.) 0.5 Glucam ~ ~-10 (Americhol) 0.7 Preservative 0.3 )5 C. Triethanolamine 0.4 Fragrance 0.1 ~0 1~3~ 6 This formulation is prepared in separate stages, as follows:
Part A of the mixture was prepared by dispersing the Carbopol in water and then stirring in the other components. All the part B components were mixed together and heated to 70C. Parts A and B were then combincd and the triethanolamine and fragrance were added. The resulting cream was stable and smooth and had goodliloisturlzing qualities and an excellent feeling on the skin.
Example 25 This example illustrates the use of the petrolatum filled cross-linked gel in a hand lotion.
~ By Wei~ht A. Carbopol ~ 0.25 Carboxymethylcellulose 9H4F, 1~ water solution 2.00 Product of Example 18 60.00 Water 36.70 B. Robane ~ 0.20 Cochin ~ 0.10 Preservative 0.30 C. Triethanolamine 0.25 Fra~rance 0.20 This Eormulation was prepared as the one described in the pre-ceding example. The resulting lotion was rich with excellent moisturizing qualities and did not give a greasy feeling on the skin.
The ingredients noted in Examples 24 and 25 by trade-mark are identified as follows:

~ -2~-~.

~23()~

Volpo-5 ~ Oleth-5 (polyethylene glycol ether of oleyl alcohol) Volpo-3 ~ Oleth-3 (polyethylene glycol ether of oleyl aLcohol) Solulan ~ C-24 Choleth-24 (polyethylene glycol ether of Cholesterol) Crodamol ~ PMP (propoY~ylated myristyl pro-pionate) PPG-3 Myristyl Ether Propionate Glucam ~ E-10 Methyl gluceth-10 (poly-ethylene glycol ether of methyl glucose) Example 26 This example illustrates the slow release of a low mole-cular weight substance dispersed in a matrix of cross-linked hyaluronic acid.
In this experiment, a radioactive labelled substance, hydroxytryptamine binoxolate, 5-[1,2-3H(N)]-, was used. 5 ~1 of a 40 ~M solution of the substance was mixed with 5 ~1 of cross-linked H~ gel particles (HA concentration in the gel 0.131~) and water, respectively. The mixtures were put into dialysis tubes and dialy~ed against 0.15M NaCl sol~ltion for 24 hours.
For the mixture of the labelled substance and the cross-linked gel, 54~ of the starting amount of the labelled material was left in the dialysis tube, whereas only 10% remained for the water solution. This demonstrates that the cross-linked gel of HA slows down the release of the low molecular weight sub-stance by a factor of more than 5 times.
Variations and modifications can, of course, be made without departin~ from the spirit and scope of the invention.

. .,

Claims (35)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIBILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A method of preparing a cross-linked gel of hyaluronic acid comprising subjecting sodium hyaluronate in a dilute aqueous alkaline solution at a pH of not less than about 9 to a cross-linking reaction with divinyl sulfone at about 20°C.
2. A method according to claim 1 wherein sodium hyaluronate has a molecular weight of about 50,000 to about 8 x 106.
3. A method according to claim 1 wherein the concen-tration of sodium hyaluronate in the reaction mixture is 1-8%
by weight.
4. A method according to claim 1 wherein the ratio of the sodium hyaluronate to divinyl sulfone is from 15:1 to 1:5 by weight.
5. A method according to claim 1 and further com-prising adding an alkali metal chloride, sulfate, phosphate or acetate to the reaction mixture in an amount sufficient to pro-vide up to about 20% by weight concentration in the mixture.
6. A method of preparing a mixed cross-linked gel of hyaluronic acid and at least one other hydrophilic polymer having a functional group capable of reacting with divinyl sulfone, said method comprising subjecting a mixture of sodium hyaluronate and said other hydrophilic polymer in a dilute aqueous alkaline solution at a pH of not less than about 9 to a cross-linking reaction with divinyl sulfone at about 20°C.
7. A method according to claim 6 wherein the other hydrophilic polymer is a natural or synthetic polysaccharide selected from the group consisting of hydroxyethyl cellulose, carboxymetnyl cellulose, xanthan gum, chondroitin sulfate and heparin, a protein selected from the group consisting of collagen, elastin, albumin, a globulin, keratin sulfate, a sulfated amino-glycosaminoglycan and a synthetic water soluble polymer.
8. A method according to claim 6 wherein sodium hyaluronate has a molecular weight of about 50,000 to about 8 x 106.
9. A method according to claim 6 wherein the com-bined concentration of sodium hyaluronate and the other hydro-philic polymers in the reaction mixture is 1-8% by weight and the sodium hyaluronate comprises from 5-95% of the total.
10. A method according to claim 6 wherein the ratio of the sodium hyaluronate to divinyl sulfone is from 15:1 to 1:5 by weight.
11. A method according to claim 6 and further com-prising adding an alkali metal chloride, sulfate, phosphate or acetate to the reaction mixture in an amount sufficient to pro-vide up to about 20% by weight concentration in the mixture.
12. A method of preparing a cross-linked gel of hyaluronic acid or a mixed cross-linked gel of hyaluronic acid and at least one other hydrophilic polymer having a functional group capable of reacting with divinyl sulfone, either of which further includes an inert water insoluble substance, said method comprising subjecting sodium hyaluronate or a mixture of sodium hyaluronate and said other hydrophilic polymer in a dilute aqueous alkaline solution at a pH of not less than about 9, to which has been added an inert water in-soluble substance to a cross-linking reaction with divinyl sulfone at about 20°C.
13. A method according to claim 12 wherein the inert water insoluble substance is a hydrocarbon, an oil or fat, a pigment, polyethylene or polytetrafluoro ethylene.
14. A method according to claim 13 wherein the hydro-carbon is petrolatum, the oil or fat is beeswax, coconut oil or lanolin, and the pigment is kaolin, ferric oxide or an insoluble dye.
15. A method according to claim 12 wherein sodium hyaluronate has a molecular weight of about 50,000 to about 8 x 106.
16. A method according to claim 12 wherein the con-centration of sodium hyaluronate or the mixture of sodium hyaluronate and the other hydrophilic polymer is 1-8% by weight and the inert water insoluble substance is present in an amount of 1-95% by weight based on the total weight of polymers plus inert water insoluble substance.
17. A method according to claim 12 wherein the ratio of the sodium hyaluronate to divinyl sulfone is from 15:1 to 1:5 by weight.
18. A method according to claim 12 and further com-prising adding an alkali metal chloride, sulfate, phosphate or acetate to the reaction mixture in an amount sufficient to pro-vide up to about 20% by weight concentration in the mixture.
19. A method of preparing a cross-linked gel of hyaluronic acid or a mixed cross-linked gel of hyaluronic acid and at least one other hydrophilic polymer having a functional group capable of reacting with divinyl sulfone, either of which further includes a low molecular weight substance co-valently bonded to the macromolecular network, said method comprising subjecting sodium hyaluronate or a mixture of sodium hyaluronate and said other hydrophilic polymer in a dilute aqueous alkaline solution at a pH of not less than about 9, to which has been added a low molecular weight sub-stance having a functional group with active hydrogen atoms reactive to divinyl sulfone to a cross-linking reaction with divinyl sulfone at about 20°C.
20. A method according to claim 19 wherein the low molecular weight substance is a drug.
21. A method according to claim 19 wherein the low molecular weight substance is a carminic acid.
22. A method according to claim 19 wherein sodium hyaluronate has a molecular weight of about 50,000 to about 8 x 106.
23. A method according to claim 19 wherein the concentration of sodium hyaluronate or the mixture of sodium hyaluronate and the other hydrophilic polymer is 1-8% by weight and the low molecular weight substance is present in an amount of 1-95% by weight based on the total weight of polymers plus inert water insoluble substance.
24. A method according to claim 19 wherein the ratio of the sodium hyaluronate to divinyl sulfone is from 15:1 to 1:5 by weight.
25. A method according to claim 19 and further comprising adding an alkali metal chloride, sulfate, phosphate or acetate to the reaction mixture in an amount sufficient to provide up to about 20% by weight concentration in the mixture.
26. A cross-linked gel of hyaluronic acid produced by the method according to claim 1.
27. A mixed cross-linked gel of hyaluronic acid and at least one other hydrophilic polymer having a functional group capable of reacting with divinyl sulfone reacted with, divinyl sulfone, wherein the combined concentration of sodium hyaluronate and the other hydrophilic polymer is 1-8% by weight and the sodium hyaluronate comprises from 5-95% of the total.
28. A gel according to claim 27 wherein the other hydrophilic polymer is a natural or synthetic polysaccharide selected from the group consisting of hydroxyethyl cellulose, carboxymethyl cellulose, xanthan gum, chondroitin sulfate and heparin, a protein selected from the group consisting of collagen, elastin, albumin, a globulin, keratin sulfate, a sulfated aminoglycosaminoglycan and a synthetic water soluble polymer.
29. A cross-linked gel of hyaluronic acid or a mixed cross-linked gel of hyaluronic acid and at least one other hydrophilic polymer having a functional group capable of reacting with divinyl sulfone reacted, with divinyl sulfone, and further comprising an inert water insoluble substance, wherein the concentration of sodium hyaluronate or the mixture of sodium hyaluronate and the other hydrophilic polymer is 1-8% by weight and the inert water insoluble substance is present in an amount of 1-95% by weight based on the total weight of polymers plus inert water insoluble substance.
30. A gel according to claim 29 wherein the inert water insoluble substance is a hydrocarbon, an oil or fat, a pigment, polyethylene or polytetrafluoroethylene.
31. A gel according to claim 30 wherein the hydrocarbon is petralatum, the oil or fat is beeswax, coconut oil or lanolin, and the pigment is kaolin, ferric oxide or an insoluble dye.
32. A cross-linked gel of hyaluronic acid or a mixed cross-linked gel of hyaluronic acid and at least one other hydrcphilic polymer having a functional group capable of reacting with divinyl sulfone reacted, with divinyl sulfone, and further comprising a low molecular weight substance covalently bonded to the macro-molecular network, wherein the concentration of sodium hyaluro-nate or the mixture of sodium hyaluronate and the other hydro-philic polymer is 1-8% by weight and the low molecular weight substance is present in an amount of 1-95% by weight based on the total weight of the polymer.
33. A gel according to claim 32 wherein the low molecular weight substance is a drug.
34. A gel according to claim 32 wherein the low molecular weight substance is carminic acid.
35. A delivery system for a substance having biological or pharmacological activity, said system comprising a molecular cage formed of a cross-linked gel of hyaluronic acid or a mixed cross-linked gel of hyaluronic acid and at least one other hydro-philic polymer co-polymerizable therewith and having dispersed therein a substance having biological or pharmacological activity and which is capable of being diffused therefrom in a controlled manner.
CA000481055A 1984-12-06 1985-05-08 Cross-linked gels of hyaluronic acid and products containing such gels Expired CA1230186A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/678,895 US4582865A (en) 1984-12-06 1984-12-06 Cross-linked gels of hyaluronic acid and products containing such gels
US678,895 1984-12-06

Publications (1)

Publication Number Publication Date
CA1230186A true CA1230186A (en) 1987-12-08

Family

ID=24724742

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000481055A Expired CA1230186A (en) 1984-12-06 1985-05-08 Cross-linked gels of hyaluronic acid and products containing such gels

Country Status (9)

Country Link
US (1) US4582865A (en)
JP (2) JPS61138601A (en)
AU (2) AU569157B2 (en)
CA (1) CA1230186A (en)
DE (2) DE3520008A1 (en)
FR (1) FR2574414B1 (en)
GB (4) GB2168067B (en)
IT (1) IT1187737B (en)
SE (2) SE460792B (en)

Families Citing this family (284)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0611694B2 (en) * 1985-01-29 1994-02-16 生化学工業株式会社 Skin cosmetics
US4863907A (en) * 1984-06-29 1989-09-05 Seikagaku Kogyo Co., Ltd. Crosslinked glycosaminoglycans and their use
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4713448A (en) * 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
US5099013A (en) * 1985-03-12 1992-03-24 Biomatrix, Inc, Hylan preparation and method of recovery thereof from animal tissues
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US5202431A (en) * 1985-07-08 1993-04-13 Fidia, S.P.A. Partial esters of hyaluronic acid
DE3684887D1 (en) * 1985-11-29 1992-05-21 Biomatrix Inc DRUG DELIVERY SYSTEMS BASED ON HYALURONANE, THEIR DERIVATIVES AND SALTS AND METHOD FOR THE PRODUCTION THEREOF.
IT1198449B (en) * 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani ESTERS OF POLYVALENT ALCOHOLS OF HYALURONIC ACID
AU610512B2 (en) * 1986-12-11 1991-05-23 Biomatrix Incorporated Improved hyaluronate-poly (ethylene oxide) mixtures
EP0356435B1 (en) * 1987-03-19 1995-10-18 Arthropharm Pty. Limited Anti-inflammatory compounds and compositions
US4795741A (en) * 1987-05-06 1989-01-03 Biomatrix, Inc. Compositions for therapeutic percutaneous embolization and the use thereof
GB8713662D0 (en) * 1987-06-11 1987-07-15 Skandigen Ab Hyaluronic acid derivatives
US6174999B1 (en) 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US6610669B1 (en) 1987-09-18 2003-08-26 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US5527893A (en) * 1987-09-18 1996-06-18 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US5017229A (en) * 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US4937270A (en) * 1987-09-18 1990-06-26 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
AU619760B2 (en) * 1987-12-10 1992-02-06 Genzyme Biosurgery Corporation Hylan preparation and method of recovery thereof from animal tissues
US4888016A (en) * 1988-02-10 1989-12-19 Langerman David W "Spare parts" for use in ophthalmic surgical procedures
IT1219587B (en) * 1988-05-13 1990-05-18 Fidia Farmaceutici SELF-CROSS-LINKED CARBOXYLY POLYSACCHARIDES
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
JPH0662678B2 (en) * 1988-11-28 1994-08-17 電気化学工業株式会社 Hyaluronic acid-immobilized protein and method for producing the same
US4973473A (en) * 1989-06-23 1990-11-27 Revlon, Inc. Skin care preparation
US5356883A (en) 1989-08-01 1994-10-18 Research Foundation Of State University Of N.Y. Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5153174A (en) * 1989-10-30 1992-10-06 Union Carbide Chemicals & Plastics Inc. Polymer mixtures useful in skin care
WO1992000745A1 (en) * 1990-07-03 1992-01-23 Autogenesis Technologies, Inc. Collagen-based viscoelastic solution for visco-surgery
US5246698A (en) * 1990-07-09 1993-09-21 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US5143724A (en) * 1990-07-09 1992-09-01 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5990096A (en) * 1990-09-18 1999-11-23 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
US5219360A (en) * 1991-05-10 1993-06-15 Fortis Research Corporation Mammary prosthesis fill and method of making same
EP0516026A1 (en) * 1991-05-28 1992-12-02 Takeda Chemical Industries, Ltd. Hydrogel and method of producing same
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
WO1994007505A1 (en) * 1991-07-03 1994-04-14 Norpharmco Inc. Use of hyaluronic acid and forms to prevent arterial restenosis
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
JPH0539480U (en) * 1991-10-31 1993-05-28 ジユーキ株式会社 Sewing machine needle bar
EP0544259A1 (en) * 1991-11-27 1993-06-02 Lignyte Co., Ltd. Water insoluble biocompatible hyaluronic and polyion complex and method of making the same
DE4200080A1 (en) * 1992-01-03 1993-09-30 Reinmueller Johannes Pharmaceutical composition for wound, scar and keloid treatment
CA2072918A1 (en) * 1992-02-14 1993-08-15 Jian Qin Modified polysaccharides having improved absorbent properties and process for the preparation thereof
US6136793A (en) * 1992-02-20 2000-10-24 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
US6218373B1 (en) 1992-02-20 2001-04-17 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5767106A (en) * 1992-02-21 1998-06-16 Hyal Pharmaceutical Corporation Treatment of disease and conditions associated with macrophage infiltration
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
DE69321285T2 (en) * 1992-05-15 1999-03-04 Shiseido Co Ltd External skin preparation
IT1260154B (en) * 1992-07-03 1996-03-28 Lanfranco Callegaro HYALURONIC ACID AND ITS DERIVATIVES IN INTERPENETRATING POLYMERS (IPN)
WO1994021299A1 (en) * 1993-03-19 1994-09-29 Medinvent A composition and a method for tissue augmentation
US5437867A (en) * 1993-03-19 1995-08-01 Collaborative Laboratories Solubilizing, thickening and emulsifying cosmetic composition and process for preparation of same
US5531716A (en) * 1993-09-29 1996-07-02 Hercules Incorporated Medical devices subject to triggered disintegration
US5616568A (en) * 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
US5585361A (en) 1994-06-07 1996-12-17 Genzyme Corporation Methods for the inhibition of platelet adherence and aggregation
US6294202B1 (en) 1994-10-06 2001-09-25 Genzyme Corporation Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers
US5690961A (en) * 1994-12-22 1997-11-25 Hercules Incorporated Acidic polysaccharides crosslinked with polycarboxylic acids and their uses
US5498705A (en) * 1995-02-22 1996-03-12 Kimberly-Clark Corporation Modified polysaccharides having improved absorbent properties and process for the preparation thereof
US5612321A (en) * 1995-06-22 1997-03-18 Hercules Incorporated Antioxidant grafted polysaccharides
US5827937A (en) * 1995-07-17 1998-10-27 Q Med Ab Polysaccharide gel composition
US5897880A (en) 1995-09-29 1999-04-27 Lam Pharmaceuticals, Llc. Topical drug preparations
AU7609896A (en) 1995-11-07 1997-05-29 Fusion Medical Technologies, Inc. Methods and articles for fusing polysaccharide-containing matrix layers to tissue
US6132462A (en) * 1995-12-22 2000-10-17 Santen Pharmaceutical Co., Ltd. Copolymers formed from three components and intraocular lenses made thereof
SE9601368D0 (en) * 1996-04-11 1996-04-11 Pharmacia Biotech Ab Process for the production of a porous cross-linked polysaccharide gel
US6368356B1 (en) 1996-07-11 2002-04-09 Scimed Life Systems, Inc. Medical devices comprising hydrogel polymers having improved mechanical properties
US6060534A (en) 1996-07-11 2000-05-09 Scimed Life Systems, Inc. Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties
EP2002846B1 (en) 1996-12-06 2017-01-25 Amgen Inc. Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
GB2322864A (en) * 1997-03-07 1998-09-09 Polybiomed Ltd Gel for application to the human or animal body
US6709873B1 (en) * 1997-04-09 2004-03-23 Isodiagnostika Inc. Method for production of antibodies to specific sites of rapamycin
CN1264390A (en) * 1997-05-28 2000-08-23 清水庆彦 Collagen gel
US5945457A (en) * 1997-10-01 1999-08-31 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science Process for preparing biologically compatible polymers and their use in medical devices
US5897988A (en) * 1998-01-21 1999-04-27 Yale University Process and system for selection of mature sperm by surface membrane determinants for assisted reproduction
EP0939086B1 (en) * 1998-02-27 2004-03-10 Stichting Hippomedics Process for producing crosslinked hyaluronic acid
US6630457B1 (en) 1998-09-18 2003-10-07 Orthogene Llc Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
IT1303738B1 (en) * 1998-11-11 2001-02-23 Aquisitio S P A CARBOXYLATE POLYSACCHARIDE CROSS-LINKING PROCESS.
US7375096B1 (en) * 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
AU767859B2 (en) * 1998-12-16 2003-11-27 Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno Acidic superabsorbent polysaccharides
GB9902412D0 (en) * 1999-02-03 1999-03-24 Fermentech Med Ltd Process
GB9902652D0 (en) 1999-02-05 1999-03-31 Fermentech Med Ltd Process
CN1288197C (en) * 1999-02-19 2006-12-06 电气化学工业株式会社 Hyaluronic acid gel composition, process for producing the same, and medical material containing the same
CA2365767A1 (en) 1999-03-15 2000-09-21 Trustees Of Boston University Angiogenesis inhibition
US20040048021A1 (en) * 1999-03-19 2004-03-11 Wan Barbara Y. F. Surface modification of substrates
CA2366897C (en) * 1999-04-06 2009-11-17 Andrew B. Onderdonk Immunomodulatory compositions and methods of use thereof
US6288043B1 (en) * 1999-06-18 2001-09-11 Orquest, Inc. Injectable hyaluronate-sulfated polysaccharide conjugates
DE60014400T2 (en) 1999-07-28 2005-10-06 United States Surgical Corp., Norwalk ANTI-ADHESION LAYER OF HYALURONIC ACID
KR100721752B1 (en) 2000-01-24 2007-05-25 쿠라레 메디카루 가부시키가이샤 Water-swellable polymer gel and process for preparing the same
US6521223B1 (en) * 2000-02-14 2003-02-18 Genzyme Corporation Single phase gels for the prevention of adhesions
US6749865B2 (en) 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
KR100375299B1 (en) 2000-10-10 2003-03-10 주식회사 엘지생명과학 Crosslinked derivatives of hyaluronic acid by amide formation and their preparation methods
AU2399502A (en) * 2000-11-14 2002-05-27 R Labs Bvi Nv Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants
DE60207831D1 (en) * 2001-02-22 2006-01-12 Anika Therapeutics Inc THIOL-MODIFIED HYALURONAN DERIVATIVES
US20020172712A1 (en) * 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
US6913765B2 (en) 2001-03-21 2005-07-05 Scimed Life Systems, Inc. Controlling resorption of bioresorbable medical implant material
US8580290B2 (en) * 2001-05-08 2013-11-12 The Board Of Regents Of The University Of Oklahoma Heparosan-based biomaterials and coatings and methods of production and use thereof
US20030216758A1 (en) * 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
AU2003221078A1 (en) * 2002-04-08 2003-10-20 Denki Kagaku Kogyo Kabushiki Kaisha Therapeutic composition for bone infectious disease
DE10223310A1 (en) * 2002-05-24 2003-12-11 Biotronik Mess & Therapieg Process for coating implants with a polysaccharide layer
PT1509256E (en) * 2002-05-24 2009-10-15 Angiotech Int Ag Compositions and methods for coating medical implants
US8313760B2 (en) * 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
CA2489712C (en) * 2002-06-21 2016-07-12 University Of Utah Research Foundation Crosslinked compounds and methods of making and using thereof
US7034127B2 (en) * 2002-07-02 2006-04-25 Genzyme Corporation Hydrophilic biopolymer-drug conjugates, their preparation and use
US7338433B2 (en) 2002-08-13 2008-03-04 Allergan, Inc. Remotely adjustable gastric banding method
WO2004016275A1 (en) * 2002-08-16 2004-02-26 Denki Kagaku Kogyo Kabushiki Kaisha Separate type medical material
BR0306183A (en) * 2002-08-28 2004-10-19 Inamed Medical Products Corp Fatigue Resistant Gastric Banding Device
CA2497792C (en) 2002-09-06 2014-08-05 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
DE10252816B4 (en) * 2002-11-13 2008-02-14 Schwan-Stabilo Cosmetics Gmbh & Co. Kg Cosmetic preparation, and a process for its preparation and its use
JP4636883B2 (en) * 2002-11-21 2011-02-23 中外製薬株式会社 Drug sustained-release carrier
TWI251596B (en) * 2002-12-31 2006-03-21 Ind Tech Res Inst Method for producing a double-crosslinked hyaluronate material
LT5098B (en) 2003-03-28 2004-01-26 Alvyda GUDELEVIČIŪTĖ Cream compositions for ageing skin
FR2861734B1 (en) 2003-04-10 2006-04-14 Corneal Ind CROSSLINKING OF LOW AND HIGH MOLECULAR MASS POLYSACCHARIDES; PREPARATION OF INJECTABLE SINGLE PHASE HYDROGELS; POLYSACCHARIDES AND HYDROGELS OBTAINED
AU2003901834A0 (en) 2003-04-17 2003-05-01 Clearcoll Pty Ltd Cross-linked polysaccharide compositions
JP2004323454A (en) * 2003-04-25 2004-11-18 Chisso Corp Medicinal agent
CN101137388A (en) * 2003-05-15 2008-03-05 犹他卅大学研究基金会 Anti-adhesion composites and methods os use thereof
ES2226567B1 (en) * 2003-06-20 2006-07-01 Universidad De Santiago De Compostela NANOPARTICULAS OF HIALURONIC ACID.
DE10328816A1 (en) * 2003-06-21 2005-01-05 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Implantable stimulation electrode with a coating to increase tissue compatibility
DE10328815A1 (en) * 2003-06-21 2005-01-05 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Coating system for implants to increase tissue compatibility
ES2232287B1 (en) * 2003-07-04 2006-11-01 Advanced In Vitro Cell Technologies, S.L. POLYOXYETHYLATE DERIVATIVES NANOPARTICLES.
CA2534033A1 (en) * 2003-07-30 2005-02-10 Anteis S.A. Complex matrix for biomedical use
ES2406555T3 (en) * 2003-10-29 2013-06-07 Teijin Limited Composed of hyaluronic acid, hydrogel thereof and material to treat joints
WO2005051451A2 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Electrical devices and anti-scarring agents
US20080176205A1 (en) * 2003-12-04 2008-07-24 University Of Utah Research Foundation Process and Formulation to Improve Viability of Stored Cells and Tissue
WO2005066215A1 (en) * 2003-12-30 2005-07-21 Genzyme Corporation Cohesive gels form cross-linked hyaluronan and/or hylan, their preparation and use
US8524213B2 (en) * 2003-12-30 2013-09-03 Genzyme Corporation Polymeric materials, their preparation and use
EP1706044B1 (en) 2004-01-23 2011-10-05 Allergan, Inc. Releasably-securable one-piece adjustable gastric band
ES2333024T3 (en) * 2004-03-08 2010-02-16 Allergan Medical S.A. CLOSURE SYSTEM FOR TUBULAR ORGANS.
CA2559520A1 (en) * 2004-03-17 2005-09-29 Genzyme Corporation Anti-adhesion spraying
EP1732635B1 (en) * 2004-03-18 2011-07-27 Allergan, Inc. Apparatus for volume adjustment of intragastric balloons
NZ550964A (en) 2004-04-28 2011-05-27 Angiodevice Internat Gmbh Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
ES2246695B1 (en) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. STIMULATING COMPOSITION OF THE IMMUNE RESPONSE THAT INCLUDES NANOPARTICLES BASED ON A COPYLIMER OF METHYL VINYL ETER AND MALEIC ANHYDRIDE.
ES2246694B1 (en) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. PEGILATED NANOPARTICLES.
ES2609105T3 (en) * 2004-05-20 2017-04-18 Mentor Worldwide Llc Covalent linking method of hyaluronic acid and chitosan
EP1750769B1 (en) * 2004-05-20 2013-01-23 Mentor Worldwide LLC Methods for making injectable polymer hydrogels
ITMI20041373A1 (en) 2004-07-09 2004-10-09 Lima Lto S P A N-METHYL-CARBOXYMETHYLCELLULOSE ACID ALGINIC OR CARBOXYMETALAMIDE
US8143391B2 (en) 2004-09-07 2012-03-27 Chugai Seiyaku Kabushiki Kaisha Process for producing water-soluble hyaluronic acid modification
CN101056891B (en) * 2004-11-15 2010-05-26 株式会社资生堂 Process for preparing crosslinked hyaluronic acid gel
DK1817347T3 (en) * 2004-11-24 2017-08-14 Albumedix As Process for Crosslinking Hyaluronic Acid with Divinyl Sulfone
EP2664335A3 (en) * 2004-12-30 2015-12-16 Genzyme Corporation Regimens for intra-articular viscosupplementation
AU2005100176A4 (en) * 2005-03-01 2005-04-07 Gym Tv Pty Ltd Garbage bin clip
US8251888B2 (en) * 2005-04-13 2012-08-28 Mitchell Steven Roslin Artificial gastric valve
DE102005030614B4 (en) * 2005-06-30 2014-05-08 Biotissue Ag Cell-free graft, its use, process for its preparation, matrix thus produced with gel and process for the preparation of this matrix with gel
EP1911769B1 (en) 2005-08-04 2013-10-30 Teijin Limited Cellulose derivative
WO2007026362A2 (en) * 2005-09-02 2007-03-08 Colbar Lifescience Ltd. Cross-linked polysaccharide and protein matrices and methods for their preparation
CA2623106C (en) 2005-09-19 2013-12-24 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
US20070203095A1 (en) * 2005-12-14 2007-08-30 Anika Therapeutics, Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
EP1968499A1 (en) 2005-12-14 2008-09-17 Anika Therapeutics Inc. Bioabsorbable implant of hyaluronic acid derivative for treatment of osteochondral and chondral defects
US7798954B2 (en) 2006-01-04 2010-09-21 Allergan, Inc. Hydraulic gastric band with collapsible reservoir
US8043206B2 (en) 2006-01-04 2011-10-25 Allergan, Inc. Self-regulating gastric band with pressure data processing
CA2645227C (en) 2006-03-07 2015-06-23 Prochon Biotech Ltd. Hydrazido derivatives of hyaluronic acid
US7674781B2 (en) * 2006-04-28 2010-03-09 Heather Sheardown Hyaluronic acid-retaining polymers
ITMI20061726A1 (en) * 2006-09-11 2008-03-12 Fidia Farmaceutici CROSSLINKATI DERIVATIVES BASED ON HYALURONIC ACID RETICULATED VIA CLICK CHEMISTRY
AU2007295894B2 (en) * 2006-09-13 2013-10-17 Enhance Skin Products, Inc. Cosmetic composition for the treatment of skin and methods thereof
JP5030219B2 (en) * 2007-07-19 2012-09-19 眞知子 瀧上 Process for producing gel of carboxymethylcellulose alkali salt and gel of carboxymethylcellulose alkali salt obtained thereby
DE102006047346A1 (en) * 2006-10-06 2008-04-10 Transtissue Technologies Gmbh Matrix gel graft without cells
EP2106263B1 (en) * 2007-01-04 2016-12-21 Hepacore Ltd. Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US8529951B1 (en) 2007-02-21 2013-09-10 Anand Ramamurthi Elastogenic cues and methods for using same
US8987230B2 (en) * 2007-05-01 2015-03-24 National University Corporation Tokyo Medical And Dental University Hybrid gel comprising chemically crosslinked hyaluronic acid derivative and pharmaceutical composition comprising the same
CA2687990A1 (en) * 2007-05-23 2008-12-04 Allergan, Inc. Cross-linked collagen and uses thereof
US8658148B2 (en) 2007-06-22 2014-02-25 Genzyme Corporation Chemically modified dendrimers
FR2918377B1 (en) 2007-07-05 2010-10-08 Estelle Piron CO-RETICLE GEL OF POLYSACCHARIDES
US20110077737A1 (en) * 2007-07-30 2011-03-31 Allergan, Inc. Tunably Crosslinked Polysaccharide Compositions
US8318695B2 (en) 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
EP3498299A1 (en) 2007-11-16 2019-06-19 Aclaris Therapeutics, Inc. Compositions and methods for treating purpura
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US8394784B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8394782B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
FR2924615B1 (en) * 2007-12-07 2010-01-22 Vivacy Lab HYDROGEL COHESIVE BIODEGRADABLE.
JP5523338B2 (en) * 2007-12-19 2014-06-18 エヴォニク ゴールドシュミット ゲーエムベーハー Cross-linked hyaluronic acid in emulsion
US7763268B2 (en) * 2008-01-18 2010-07-27 The Research Foundation Of State University Of New York Load bearing hydrogel implants
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
EP3184552B1 (en) 2008-09-02 2020-08-12 Tautona Group LP Threads of hyaluronic acid, methods of making thereof and uses thereof
TWI387620B (en) * 2008-09-23 2013-03-01 Scivision Biotech Inc Method for producing cross-linked hyaluronic acid
WO2010038231A1 (en) 2008-10-02 2010-04-08 L.R.R.& D. Ltd. Interface layer wound dressing
US8317677B2 (en) * 2008-10-06 2012-11-27 Allergan, Inc. Mechanical gastric band with cushions
US20100305397A1 (en) * 2008-10-06 2010-12-02 Allergan Medical Sarl Hydraulic-mechanical gastric band
CN101721349B (en) 2008-10-16 2011-07-20 常州百瑞吉生物医药有限公司 Injectable in-situ crosslinking aquogel and preparation method and application thereof
US20100185049A1 (en) 2008-10-22 2010-07-22 Allergan, Inc. Dome and screw valves for remotely adjustable gastric banding systems
CZ2008705A3 (en) 2008-11-06 2010-04-14 Cpn S. R. O. Process for preparing DTPA crosslinked derivatives of hyaluronic acid and their modifications
US8679470B2 (en) 2008-11-28 2014-03-25 Luromed Llc Composition using cross-linked hyaluronic acid for topical cosmetic and therapeutic applications
JP2010202522A (en) * 2009-02-27 2010-09-16 Shiseido Co Ltd Salt-resistant thickener and cosmetic comprising the same
WO2010115081A2 (en) * 2009-04-02 2010-10-07 Allergan, Inc. Hair-like shaped hydrogels for soft tissue augmentation
US9371402B2 (en) 2009-04-09 2016-06-21 Scivision Biotech Inc. Method for producing cross-linked hyaluronic acid
US20110184229A1 (en) * 2009-05-01 2011-07-28 Allergan, Inc. Laparoscopic gastric band with active agents
EP2424583A2 (en) * 2009-05-01 2012-03-07 Allergan, Inc. Laparoscopic gastric band with active agents
IT1399351B1 (en) 2009-06-16 2013-04-16 Fidia Farmaceutici PROCEDURE FOR THE SYNTHESIS OF GLYCOSAMINOGLICAN CONJUGATES (GAG) WITH BIOLOGICALLY ACTIVE MOLECULES, POLYMERIC CONJUGATES AND RELATIVE USES
KR101551681B1 (en) 2009-07-30 2015-09-09 카르빌란 테라퓨틱스, 인코포레이티드 Modified hyaluronic acid polymer compositions and related methods
WO2011031400A2 (en) * 2009-08-28 2011-03-17 Allergan, Inc. Gastric band with electric stimulation
US20110137112A1 (en) * 2009-08-28 2011-06-09 Allergan, Inc. Gastric band with electric stimulation
US8273725B2 (en) 2009-09-10 2012-09-25 Genzyme Corporation Stable hyaluronan/steroid formulation
US8247390B2 (en) * 2009-09-28 2012-08-21 Luromed Llc Modified hydrophilic polymers containing hydrophobic groups
JP6220126B2 (en) * 2009-11-23 2017-10-25 セルリアン・ファーマ・インコーポレイテッド Polymers based on cyclodextrins for therapeutic delivery
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US20110171286A1 (en) * 2010-01-13 2011-07-14 Allergan, Inc. Hyaluronic acid compositions for dermatological use
US20110171311A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Stable hydrogel compositions including additives
US8758221B2 (en) * 2010-02-24 2014-06-24 Apollo Endosurgery, Inc. Source reservoir with potential energy for remotely adjustable gastric banding system
US8840541B2 (en) * 2010-02-25 2014-09-23 Apollo Endosurgery, Inc. Pressure sensing gastric banding system
CA2792729C (en) 2010-03-12 2016-06-28 Allergan Industrie, Sas Fluid compositions for improving skin conditions
CA2794254C (en) 2010-03-22 2018-09-04 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US9028394B2 (en) 2010-04-29 2015-05-12 Apollo Endosurgery, Inc. Self-adjusting mechanical gastric band
US20110270024A1 (en) 2010-04-29 2011-11-03 Allergan, Inc. Self-adjusting gastric band having various compliant components
US9044298B2 (en) 2010-04-29 2015-06-02 Apollo Endosurgery, Inc. Self-adjusting gastric band
US20110270025A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Remotely powered remotely adjustable gastric band system
US8517915B2 (en) 2010-06-10 2013-08-27 Allergan, Inc. Remotely adjustable gastric banding system
US9017712B2 (en) 2010-07-12 2015-04-28 Shin Poong Pharmaceutical Co., Ltd. Filler composition for tissue reinforcement
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US20120059216A1 (en) 2010-09-07 2012-03-08 Allergan, Inc. Remotely adjustable gastric banding system
US8961393B2 (en) 2010-11-15 2015-02-24 Apollo Endosurgery, Inc. Gastric band devices and drive systems
CZ303548B6 (en) 2011-01-05 2012-11-28 Contipro Pharma A.S. Iodine-forming health formulation, process of its preparation and bandage containing thereof
WO2012140650A2 (en) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
US9381269B2 (en) 2011-04-13 2016-07-05 Avent, Inc. Biosorbable wound treatment device, process for making, and method of using the same
DK2699274T3 (en) 2011-04-20 2015-06-15 Carbylan Therapeutics Inc In situ gelling formations
ITTO20110428A1 (en) 2011-05-13 2012-11-14 Rottapharm Spa ESTERS OF HYALURONIC ACID, THEIR PREPARATION AND USE IN DERMATOLOGY
US9149422B2 (en) 2011-06-03 2015-10-06 Allergan, Inc. Dermal filler compositions including antioxidants
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
EP2720722A4 (en) 2011-06-16 2014-12-03 Univ Hong Kong Science & Techn Multi-vinylsulfone containing molecule
US10865383B2 (en) 2011-07-12 2020-12-15 Lineage Cell Therapeutics, Inc. Methods and formulations for orthopedic cell therapy
PL2742070T3 (en) 2011-08-10 2022-01-31 Glycores 2000 Srl Degradation-resistant cross-linked, low-molecular-weight hyaluronate
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US20140256695A1 (en) * 2011-11-11 2014-09-11 Phi Nguyen Injectable filler
FR2983483B1 (en) 2011-12-02 2014-11-14 Vivacy Lab PROCESS FOR SIMULTANEOUS SUBSTITUTION AND RETICULATION OF A POLYSACCHARIDE VIA ITS HYDROXYL FUNCTIONS
US8876694B2 (en) 2011-12-07 2014-11-04 Apollo Endosurgery, Inc. Tube connector with a guiding tip
US8961394B2 (en) 2011-12-20 2015-02-24 Apollo Endosurgery, Inc. Self-sealing fluid joint for use with a gastric band
JP6316537B2 (en) * 2011-12-20 2018-04-25 三洋化成工業株式会社 Branched hyaluronic acid and method for producing the same
WO2013109959A1 (en) * 2012-01-18 2013-07-25 University Of Kansas Hyaluronic acid particles and their use in biomedical applications
WO2013149161A1 (en) 2012-03-30 2013-10-03 Deangelis Paul L High molecular weight heparosan polymers and methods of production and use thereof
CZ2012282A3 (en) 2012-04-25 2013-11-06 Contipro Biotech S.R.O. Crosslinked hyaluronate derivative, process of its preparation, hydrogel and microfibers based thereon
ITPD20120173A1 (en) 2012-05-31 2013-12-01 Fidia Farmaceutici "NEW HYDROPHOBIC PROTEIN RELEASE SYSTEM"
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US20160228603A1 (en) * 2013-04-12 2016-08-11 Miba Medical Inc. Body augmentation device
CN103333349A (en) * 2013-06-28 2013-10-02 陕西巨子生物技术有限公司 Hyaluronic acid-collagen composite hydrogel for injection and preparation method thereof
EP3013865B1 (en) * 2013-06-28 2019-10-23 Galderma S.A. Method for manufacturing a shaped cross-linked hyaluronic acid product
EP2832378A2 (en) 2013-08-01 2015-02-04 Ivis Technologies S R L Adhesive biopolymer suitable for use as temporary replacement of the epithelium.
TWI482634B (en) 2013-10-24 2015-05-01 Ind Tech Res Inst Biomedical composition
KR101459070B1 (en) 2013-12-09 2014-11-17 (주) 뉴메딕 Long lasting crosslinked polysaccharide gel formulation
AR099900A1 (en) 2014-04-01 2016-08-24 Merz Pharma Gmbh & Co Kgaa FILLINGS FOR SOFT FABRICS WITH POLYSACARIDS WITH IMPROVED PERSISTENCE, KIT, PROCEDURE, USE
KR20170070008A (en) 2014-08-15 2017-06-21 더 존스 홉킨스 유니버시티 Composite material for tissue restoration
WO2016051219A1 (en) 2014-09-30 2016-04-07 Allergan Industrie, Sas Stable hydrogel compositions including additives
KR101694121B1 (en) 2014-10-28 2017-01-10 (주)헵틸와이 Double crosslinked biocompatible porous sheet and manufacturing method thereof
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
KR101521058B1 (en) 2014-12-08 2015-05-15 이노팜 주식회사 Biocompatible Composition And Method For Producing Thereof
CN104530460A (en) * 2014-12-19 2015-04-22 大连理工大学 Glycosylated high polymer material and preparation method thereof
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
CN107921237A (en) 2015-04-27 2018-04-17 反射医学公司 Sympathetic nerve cardiopulmonary neural modulation system and method
ES2872551T3 (en) * 2015-06-30 2021-11-02 Merz Pharma Gmbh & Co Kgaa Method for the production of cross-linked hyaluronic acid
KR101818705B1 (en) 2015-07-20 2018-01-16 포항공과대학교 산학협력단 Cross-linked hyaluronic acid hydrogel encapsulating therapeutic drugs and uses thereof
KR20170025778A (en) 2015-08-31 2017-03-08 대화제약 주식회사 Biocompatible polymer hyaluronic acid derivative comprising antioxidants, and crosslinked product hydrogel of the hyaluronic acid derivative
EP3673927A1 (en) * 2015-11-18 2020-07-01 LifeCell Corporation Hydrogel coated mesh
WO2017139487A1 (en) 2016-02-09 2017-08-17 Northwind Medical, Inc. Methods, agents, and devices for local neuromodulation of autonomic nerves
KR101866310B1 (en) 2016-05-31 2018-06-11 주식회사 글랜젠 Skin filling material having improved durability and antioxidative activity and the maufacturing method thereof
CN110035754A (en) 2016-06-29 2019-07-19 图拉维治疗股份有限公司 Pass through the local nerve adjustment for the treatment of septicemia and the related inflammatory patient's condition of autonomic nerves system
CA3035659C (en) * 2016-09-16 2022-09-06 Glycologix, Llc Sulfated glycosaminoglycan biomaterials as proteoglycan mimics
CZ2016826A3 (en) 2016-12-22 2018-07-04 Contipro A.S. A medicinal agent with a carrier based on hyaluronan and/or its derivatives, a method of the manufacture and use
CN110603268B (en) 2017-02-02 2022-05-17 阿米蒂比奥有限公司 Hydrogel using hyaluronic acid derivative modified with galloyl group as substrate and use thereof
US20190240335A1 (en) 2018-02-07 2019-08-08 Promedon S.A. Biocompatible Hydrogel Compositions
WO2019191405A1 (en) * 2018-03-29 2019-10-03 Ayyala Ramesh S Methods and compositions for delivery of a therapeutic agent
CN112384258A (en) 2018-05-09 2021-02-19 约翰·霍普金斯大学 Nanofiber-hydrogel composites for cell and tissue delivery
MA52880A (en) * 2018-06-15 2021-09-22 Croma Pharma Ges M B H HYDROGEL COMPOSITION CONTAINING A CROSS-LINKED POLYMER
CN117599244A (en) 2018-07-02 2024-02-27 图拉维治疗股份有限公司 Method and apparatus for forming nerve caps in situ
CA3105709C (en) 2018-07-06 2024-03-12 Lg Chem, Ltd. Hyaluronic acid filler having high viscoelasticity and high cohesiveness
CA3106381C (en) 2018-07-10 2024-02-13 Lg Chem, Ltd. Hyaluronic acid filler having high lift capacity and low injection force
AU2019401735B2 (en) 2018-12-20 2022-08-25 Lg Chem, Ltd. Filler having excellent filler properties comprising hyaluronic acid hydrogel
EP3900750A4 (en) 2018-12-21 2022-02-16 LG Chem, Ltd. Filler comprising hyaluronic acid hydrogel having excellent filling properties
KR102162724B1 (en) 2020-03-24 2020-10-07 바이오플러스 주식회사 Cross-linked hyaluronic acid gel and preparation method thereof
WO2021201150A1 (en) 2020-03-31 2021-10-07 株式会社クレハ Bioabsorbable medical material
KR102366394B1 (en) * 2021-01-05 2022-02-23 조광용 A hyaluronic acid bead gel having high swelling characteristics
KR20220106283A (en) 2021-01-22 2022-07-29 (주)앰틱스바이오 A wound dressing based on auto crosslinking hyalironic acid derivatives
KR102598899B1 (en) * 2021-05-13 2023-11-07 주식회사 바이오스탠다드 Hyaluronic acid-based functional hydrogel complex and manufacturing method thereof
WO2023010115A1 (en) * 2021-07-30 2023-02-02 Regents Of The University Of Minnesota Biomaterials for embolization and drug delivery
CN117915964A (en) 2021-09-09 2024-04-19 太阳生物公司 Sol-gel conversion of 6-arm PEG hydrogels over time

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1047380B (en) * 1954-08-18 1958-12-24 American Home Prod Process for the production of a hyaluronidase-free, partially depolymerized hyaluronic acid containing aqueous carrier solution for pharmaceuticals
DE1043589B (en) * 1956-01-02 1958-11-13 Kisaku Ibe Skin and hair care products and processes for their manufacture
US3357784A (en) * 1964-09-30 1967-12-12 Kendall & Co Exposure to intense ultraviolet light to improve characteristics of cellulosic fabrics in divinyl sulfone and glyoxal cross-linking processes
SE361320B (en) * 1972-03-14 1973-10-29 Exploaterings Ab Tbf
US4152170A (en) 1975-06-18 1979-05-01 Sumitomo Chemical Company, Ltd. Cross-linked pullulan
GB1515963A (en) * 1975-07-15 1978-06-28 Massachusetts Inst Technology Crosslinked collagen-mucopolysaccharide composite materials
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4303676A (en) * 1980-03-21 1981-12-01 Balazs Endre A Hyaluronate based compositions and cosmetic formulations containing same
JPS59162779A (en) * 1983-03-04 1984-09-13 Toshiba Corp Controlling method of frequency converter
US4448718A (en) * 1983-09-13 1984-05-15 Massachusetts Institute Of Technology Method for the preparation of collagen-glycosaminoglycan composite materials
US4487865A (en) * 1983-12-15 1984-12-11 Biomatrix, Inc. Polymeric articles modified with hyaluronate
CA1238043A (en) * 1983-12-15 1988-06-14 Endre A. Balazs Water insoluble preparations of hyaluronic acid and processes therefor
US4500676A (en) * 1983-12-15 1985-02-19 Biomatrix, Inc. Hyaluronate modified polymeric articles
US4713448A (en) * 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues

Also Published As

Publication number Publication date
DE3546811C2 (en) 1993-09-02
GB8817772D0 (en) 1988-09-01
AU572419B2 (en) 1988-05-05
DE3520008C2 (en) 1991-10-10
SE8503486L (en) 1986-06-07
GB2205848B (en) 1989-05-24
JPH02138346A (en) 1990-05-28
IT1187737B (en) 1987-12-23
AU569157B2 (en) 1988-01-21
GB2181148A (en) 1987-04-15
GB2181148B (en) 1989-06-07
GB2181147A (en) 1987-04-15
AU7217387A (en) 1987-08-27
SE8901672D0 (en) 1989-05-10
SE8901672L (en) 1989-05-10
JPS61138601A (en) 1986-06-26
GB8618719D0 (en) 1986-09-10
GB2168067A (en) 1986-06-11
GB8618720D0 (en) 1986-09-10
SE460792B (en) 1989-11-20
FR2574414B1 (en) 1987-07-03
GB2181147B (en) 1989-06-07
US4582865A (en) 1986-04-15
SE8503486D0 (en) 1985-07-15
SE501828C2 (en) 1995-05-22
GB8512072D0 (en) 1985-06-19
JPH0430961B2 (en) 1992-05-25
FR2574414A1 (en) 1986-06-13
GB2205848A (en) 1988-12-21
DE3520008A1 (en) 1986-06-19
AU4304585A (en) 1986-06-12
IT8522089A0 (en) 1985-09-09
GB2168067B (en) 1989-06-07
JPH0637575B2 (en) 1994-05-18

Similar Documents

Publication Publication Date Title
CA1230186A (en) Cross-linked gels of hyaluronic acid and products containing such gels
US4605691A (en) Cross-linked gels of hyaluronic acid and products containing such gels
US4636524A (en) Cross-linked gels of hyaluronic acid and products containing such gels
CA1276143C (en) Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
EP0224987B1 (en) Drug delivery systems based on hyaluronan, derivatives thereof and their salts and method of producing same
Muzzarelli Carboxymethylated chitins and chitosans
Holme et al. Chitosan N-sulfate. A water-soluble polyelectrolyte
AU773628B2 (en) Process for cross-linking hyaluronic acid to polymers
JP2684208B2 (en) Method for producing water-insoluble biocompatible gel
US5099013A (en) Hylan preparation and method of recovery thereof from animal tissues
EP1753787B1 (en) Method of covalently linking hyaluronan and chitosan
US7521434B2 (en) Cross-linked gels of hyaluronic acid with hydrophobic polymers and processes for making them
JP5340093B2 (en) Method for producing crosslinked hyaluronic acid
JP2022550778A (en) Hyperbranched polyglycerol polyglycidyl ethers and their use as crosslinkers for polysaccharides
CN1837265A (en) Process for composite modification of hyaluronic acid and carboxymethyl cellulose
EP0939086B1 (en) Process for producing crosslinked hyaluronic acid
EP2844310B1 (en) Shape-memory cross-linked polysaccharides
Burchard Networks in nature
CN107540763B (en) Method for preparing injection type long-acting hyaluronic acid gel by using biological cross-linking agent
Nahar et al. Alginates: The Wonder Molecule and its Gelling Techniques
RU2788454C1 (en) Method for producing hybrid preparation of bromelain and carboxymethylcellulose in the form of a dense solution
Schuerch Biomedical applications of polysaccharides

Legal Events

Date Code Title Description
MKEX Expiry